Bivatuzumab is a monoclonal antibody designed for targeted therapy, primarily in the treatment of certain types of cancer. It is engineered to bind specifically to the protein expressed on the surface of cancer cells, facilitating the immune system's ability to recognize and destroy these cells. The substance is characterized by its high specificity and affinity for its target, which enhances its therapeutic efficacy while minimizing damage to healthy tissues. Bivatuzumab is often utilized in conjunction with other therapeutic agents to improve treatment outcomes. Its mechanism of action typically involves antibody-dependent cellular cytotoxicity (ADCC) and may also include direct induction of apoptosis in targeted cells. As a biopharmaceutical, it is produced through recombinant DNA technology, ensuring a consistent and high-quality product. The development and clinical application of Bivatuzumab are subject to rigorous regulatory scrutiny to ensure safety and efficacy in patients. Overall, Bivatuzumab represents a significant advancement in the field of targeted cancer therapies, reflecting the ongoing evolution of personalized medicine.

Bivatuzumab

214559-60-1: Bivatuzumab is a monoclonal antibody designed for targeted therapy, primarily in the treatment of certain types of cancer. It is engineered to bind specifically to the protein expressed on the surface of cancer cells, facilitating the immune system's ability to recognize and destroy these cells. The substance is characterized by its high specificity and affinity for its target, which enhances its therapeutic efficacy while minimizing damage to healthy tissues. Bivatuzumab is often utilized in conjunction with other therapeutic agents to improve treatment outcomes. Its mechanism of action typically involves antibody-dependent cellular cytotoxicity (ADCC) and may also include direct induction of apoptosis in targeted cells. As a biopharmaceutical, it is produced through recombinant DNA technology, ensuring a consistent and high-quality product. The development and clinical application of Bivatuzumab are subject to rigorous regulatory scrutiny to ensure safety and efficacy in patients. Overall, Bivatuzumab represents a significant advancement in the field of targeted cancer therapies, reflecting the ongoing evolution of personalized medicine.

<p>Bivatuzumab (BIWA 4) is a humanized monoclonal antibody against CD44v6.</p>

Humanized anti-CD44 v6 monoclonal antibody; used in radiotherapy when linked to radioisotopes

CAS 214559-60-1

Bivatuzumab

Bivatuzumab

Ref: 54-BUP20258

Bivatuzumab

Ref: TM-T77480

Bivatuzumab

Ref: 3D-CLA1214